LONDON, UK: Apollon Formularies plc, a fully licensed medical cannabis company with its operations in Jamaica, announced that Apollon Formularies Jamaica has signed a long-term lease for its first International Cancer Institute in the Jamaican capital, Kingston.
The new facility will specialise in Complementary and Alternative Medical treatments (“CAM”), for cancer patients. These treatments will include Apollon’s medical cannabis products.
The new facility will allow Apollon to expand its patient treatment programme for both Jamaican and international medical patients, and at the same time generating additional revenue for the Company.
Alongside benefiting Apollon’s patients, the expansion with this facility brings the opportunity to gather invaluable patient data on the Company’s medical cannabis formulations. Additionally, this new central location provides Apollon with a facility in the country’s key medical hub.
Securing this facility follows Apollon’s recent announcement, on 18 May 2021, which stated that its medical cannabis formulations in specific combinations were effective in killing nearly 100% of living HER2+ cancer cells in 3D cell culture by direct cytotoxicity. The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon’s CLA licensed affiliate, Apollon Jamaica.
Stephen D. Barnhill, M.D., CEO of Apollon, commented, “We are very excited to be opening the Apollon International Cancer institute in Jamaica which will enable us to begin treating cancer patients using Apollon’s CAM treatments. This is a milestone for the Company as it is Apollon’s first wholly owned facility, treating patients using the Apollon Formularies medical cannabis formulations. Additionally, it gives us a unique opportunity to gather invaluable data to fully determine the efficacy of Apollon’s formulations directly on patients.
“It is our unique suite of licenses, along with the fact that licensed medical doctors in Jamaica are permitted to write prescriptions for Apollon medical cannabis products using formulations inclusive of THC, that makes the Company unique amongst its listed peers in Europe.”
Mr. Paul Burke, Chairman and CEO of Apollon Jamaica, commented, “We are very proud to be opening this facility and provide Apollon Formularies’ medical cannabis treatments to Jamaicans, as well as patients traveling from international locations. To oversee the facility, we are assembling a team of highly qualified licensed Jamaican physicians, who are experienced in treating cancer patients and are fully knowledgeable in quality, complementary and alternative medical care.”
Leave a Reply